EP2349411B1 - Pen needle assembly for intradermal medication injection - Google Patents
Pen needle assembly for intradermal medication injection Download PDFInfo
- Publication number
- EP2349411B1 EP2349411B1 EP09825133.3A EP09825133A EP2349411B1 EP 2349411 B1 EP2349411 B1 EP 2349411B1 EP 09825133 A EP09825133 A EP 09825133A EP 2349411 B1 EP2349411 B1 EP 2349411B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hub
- needle assembly
- inner shell
- pen needle
- shell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002347 injection Methods 0.000 title claims description 44
- 239000007924 injection Substances 0.000 title claims description 44
- 239000003814 drug Substances 0.000 title claims description 33
- 229940079593 drug Drugs 0.000 title description 25
- 238000012377 drug delivery Methods 0.000 claims description 18
- 239000012790 adhesive layer Substances 0.000 claims description 9
- 210000003491 skin Anatomy 0.000 description 20
- 239000010410 layer Substances 0.000 description 14
- 230000008901 benefit Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 4
- 206010069803 Injury associated with device Diseases 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940090048 pen injector Drugs 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
- A61M5/425—Protruding skin to facilitate piercing, e.g. vacuum cylinders, vein immobilising means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/46—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for controlling depth of insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/27—General characteristics of the apparatus preventing use
- A61M2205/273—General characteristics of the apparatus preventing use preventing reuse, e.g. of disposables
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/50—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
Definitions
- the present invention relates generally to a pen needle assembly for a drug delivery pen for intradermal medication injection. More particularly, the present invention generally relates to a pen needle assembly that facilitates intradermal medication injection. Still more particularly, the present invention provides a pen needle assembly that lifts the outer skin layer to facilitate intradermal medication injection.
- Insulin and other injectable medications are commonly given with drug delivery pens, whereby a disposable pen needle assembly is attached to facilitate drug container access and allow fluid egress from the container through the needle into the patient.
- Drug delivery pens such as the exemplary pen injector 100 shown in FIGS. 1 and 2 , typically comprise a dose knob/button 24, an outer sleeve 13, and a cap 21.
- the dose knob/button 24 allows a user to set the dosage of medication to be injected.
- the outer sleeve 13 is gripped by the user when injecting medication.
- the cap 21 is used by the user to securely hold the pen injector device 100 in a shirt pocket, purse or other suitable location and provide cover/protection from accidental needle injury.
- FIG. 2 is an exploded view of the drug delivery pen 100 of FIG. 1 .
- the dose knob/button 24 has a dual purpose and is used both to set the dosage of the medication to be injected and to inject the dosed medicament via the leadscrew 7 and stopper 15 through the medicament cartridge 12, which is attached to the drug delivery pen through a lower housing 17.
- the dosing and delivery mechanisms are all found within the outer sleeve 13 and are not described in greater detail here as they are understood by those knowledgeable of the prior art.
- the distal movement of the plunger or stopper 15 within the medicament cartridge 12 causes medication to be forced into the needle 11 of the hub 20.
- the medicament cartridge 12 is sealed by septum 16, which is punctured by a septum penetrating needle cannula 18 located within the hub 20.
- the hub 20 is preferably screwed onto the lower housing 17, although other attachment means can be used, such as attaching to the cartridge.
- an outer cover 69 which attaches to the hub 20, covers the hub.
- An inner shield 59 covers the patient needle 11 within the outer cover 69.
- the inner shield 59 can be secured to the hub 20 to cover the patient needle by any suitable means, such as an interference fit or a snap fit.
- the outer cover 69 and the inner shield 59 are removed prior to use.
- the cap 21 fits snugly against outer sleeve 13 to allow a user to securely carry the drug delivery pen 100.
- the medicament cartridge 12 is typically a glass tube sealed at one end with the septum 16 and sealed at the other end with the stopper 15.
- the septum 16 is pierceable by a septum penetrating cannula 18 in the hub 20, but does not move with respect to the medicament cartridge 12.
- the stopper 15 is axially displaceable within the medicament cartridge 12 while maintaining a fluid tight seal.
- a pen needle assembly as defined in claim 1 is provided that provides improved contact with a patient's skin to facilitate intradermal medication injection.
- a pen needle assembly for a drug delivery pen for intradermal medication injection transmits a desired amount of a drug solution or suspension into a patient's intradermal layer both accurately and without loss of the drug solution or suspension.
- the pen needle assembly includes a user activated stamping mechanism that facilitates intradermal medication injection.
- the pen needle assembly includes an adhesive layer to provide good contact between the pen needle assembly and the patient's skin, in addition to maintaining the needle in the intradermal layer during an injection.
- the pen needle assembly lifts the outer layer of skin during the injection after the needle has been inserted, thereby reducing back pressure generated during the injection and substantially preventing leakage.
- the pen needle assembly may include a self-locking mechanism to substantially prevent the pen needle assembly from being re-used.
- FIGS. 1 and 2 may more broadly apply to a pen needle assembly for use in conjunction with, or incorporated onto, other injection devices, such as a syringe.
- the pen needle assembly 111 includes an intradermal needle 121 fixed in a movable needle hub 131.
- a first end 143 of a first spring 141 is connected to an outer shell 151, and a second end 145 of the first spring is connected to an inner shell 171.
- a first end 163 of a second spring 161 is connected to the inner shell 171, and the second end 165 of the second spring 161 is connected to the movable needle hub 131.
- a safety cap 181, as shown in FIG. 5 is disposed over the needle 121.
- the outer shell 151 has a base 153 with an opening 155 therein.
- a wall 157 extends substantially perependicularly from the base 153.
- the base 153 and the opening 155 are each substantially circular.
- Tabs 159 are diametrically opposed on an inner surface 158 of the wall 157 of the outer shell 151.
- a free end 156 of the wall 157 is adapted to engage a patient's skin at an injection site.
- the inner shell 171 has a first end 177 and a second end 179 and is preferably substantially cylindrical. Threads 173 are disposed on an inner surface 172 thereof and are adapted to engage the lower housing 17 ( FIG. 2 ).
- a flange 174 extends outwardly from an outer surface 176 of the inner shell.
- the flange 174 has an upper surface 178 and a lower surface 170.
- a locking prong 175 extends downwardly from a lower surface 170 of the flange 174.
- the hub 131 has a base 133 with an opening 135 therein.
- a wall 137 extends substantially perependicularly from the base 133.
- the base 133 and the opening 135 are each substantially circular.
- Flexible actuators 139 are formed in the wall 137 and are diametrically opposed.
- a projection 138 is formed at the free end of each actuator 139. The projections 138 are adapted to engage the tabs 159 of the outer shell 151 prior to an injection.
- a protrusion 134 extends upwardly from an inner surface 132 of the base 133.
- a passageway 136 extends through the entirety of the protrusion 134 to the opening 135 in the base 133 of the hub 131.
- a retaining latch 201 has a base 203 and diametrically opposed arms 205 extending upwardly therefrom.
- the base has an opening 207 adapted to receive the hub protrusion 134.
- a hook 209 is formed at the free end of each of the arms 205. The hooks are adapted to engage the locking prongs 175 of the inner shell 171 prior to an injection.
- An upper surface 195 of the adhesive layer 191 is secured to a lower surface 130 of the hub base 133.
- the adhesive layer is substantially circular and corresponds to the shape of the hub base 133.
- An opening 193 in the adhesive layer 191 is aligned with the opening 135 in the hub base 133.
- a lower surface 197 of the adhesive layer 191 is adapted to contact a patient's skin at the injection site during an injection.
- a first spring 141 is disposed between the outer shell 151 and the inner shell 171.
- a first end 143 of the first spring 141 is connected to the base 153 of the outer shell 171 and a second end 145 of the first spring 141 is connected to the upper surface 178 of the flange 174 of the inner shell 171.
- a second spring 161 is disposed between the inner shell 171 and the hub 131.
- a first end 163 of the second spring 161 is connected to the lower surface 170 of the flange 174 of the inner shell 171 and a second end 165 of the second spring 161 is connected to the upper surface 132 of the hub base 133.
- a needle 121 is received by the passageway 136 in the hub protrusion 134.
- the needle 121 has a non-patient end 123 that is adapted to pierce the cartridge septum 16 ( FIG. 2 ) and a patient end 125 that passes through the opening 135 in the hub base 133 and is adapted to pierce a patient's skin at the injection site during an injection.
- FIG. 5 An assembled pen needle assembly 111 is shown in FIG. 5 .
- the threads 173 of the inner shell receive a threaded portion of the lower housing 17 ( FIG. 2 ), which is not shown in FIGS. 5 - 8 for clarity.
- a safety cap 181 is disposed over the outer shell 151 and is secured thereto in any suitable manner, such as an interference fit. The safety cap 181 prevents an accidental needle stick.
- the first spring 141 between the outer shell 151 and the inner shell 171 is in a relaxed position.
- the second spring 161 between the inner shell 171 and the hub 131 is in a compressed position.
- the hook 209 of the retaining latch 201 receives the locking prong 175 of the inner shell 171, thereby preventing movement of the inner shell.
- the hub projections 138 engage the tabs 159 of the outer shell 151, thereby preventing movement of the hub 131 and outer shell.
- the safety cap 181 is removed.
- the drug delivery pen is pushed against the patient's skin 211 such that the free end 156 of the outer shell 151 contacts the patient's skin.
- the outer shell 151 is moved upwardly (away from the patient's skin 211) along a longitudinal axis, as shown in FIG. 6 . This movement of the outer shell 151 causes the hub projections 138 to flex and move radially inwardly, thereby unlocking the locking mechanism between the retaining latch hook 209 and the locking prong 175.
- the second spring 161 is able to uncompress and extend.
- This movement of the second spring 161 urges the movable hub 131 and the needle 121 downwardly, thereby inserting the needle 121 into an intradermal layer of the patient's skin 211 at the injection site 213.
- This movement also causes the first spring 141 to become stretched.
- the adhesive layer 191 on the needle hub 131 adheres onto an outer layer of the patient's skin 211.
- the second spring 161 is then in either a relaxed or slightly compressed position.
- the pushing force on the drug delivery pen is released.
- Releasing such force on the inner shell causes the first spring 141 to return to its original position, thereby lifting the inner shell 171, the needle hub 131 and the patient's skin 211 adhered to the adhesive layer 191 upwardly.
- the retraction of the needle hub 131 lifts the adhered outer skin layer, thereby creating space in the intradermal layer to facilitate the intradermal medication injection.
- the pen needle assembly 111 is detached from the drug delivery pen 100 ( FIGS. 1 and 2 ) and is properly disposed of.
- the hub projections 138 and the outer shell tabs 159 have sloped surfaces, as shown in FIG. 8 . Such sloped prevent upward movement of the hub 131, such that the pen needle assembly 111 cannot be re-used. Because the hub 131 cannot be moved past the projections 159, the second spring 161 cannot be recompressed to drive another needle insertion.
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Description
- This application claims the benefit under 35 U.S.C. § 119(e) of
U.S. Provisional Application Serial No. 61/193,234, filed November 7, 2008 - The present invention relates generally to a pen needle assembly for a drug delivery pen for intradermal medication injection. More particularly, the present invention generally relates to a pen needle assembly that facilitates intradermal medication injection. Still more particularly, the present invention provides a pen needle assembly that lifts the outer skin layer to facilitate intradermal medication injection.
- Insulin and other injectable medications are commonly given with drug delivery pens, whereby a disposable pen needle assembly is attached to facilitate drug container access and allow fluid egress from the container through the needle into the patient.
- As technology and competition advance, driving the desire for shorter, thinner, less painful, and more efficacious injections, the design of the pen needle assembly and parts thereof becomes more and more important. Designs need to proactively address ergonomically improving injection technique, injection depth control and accuracy, the ability to be safely used and transported to disposal, and protection against misuse while maintaining the ability to be economically manufactured on a mass production scale.
- The assembly and operation to a typical drug delivery pen, as shown in
FIGS. 1 and2 , is described inU.S. Patent Application Publication No. 2006/0229562 , published on October 12, 2006. - Drug delivery pens, such as the
exemplary pen injector 100 shown inFIGS. 1 and2 , typically comprise a dose knob/button 24, anouter sleeve 13, and acap 21. The dose knob/button 24 allows a user to set the dosage of medication to be injected. Theouter sleeve 13 is gripped by the user when injecting medication. Thecap 21 is used by the user to securely hold thepen injector device 100 in a shirt pocket, purse or other suitable location and provide cover/protection from accidental needle injury. -
FIG. 2 is an exploded view of thedrug delivery pen 100 ofFIG. 1 . The dose knob/button 24 has a dual purpose and is used both to set the dosage of the medication to be injected and to inject the dosed medicament via theleadscrew 7 and stopper 15 through themedicament cartridge 12, which is attached to the drug delivery pen through alower housing 17. In standard drug delivery pens, the dosing and delivery mechanisms are all found within theouter sleeve 13 and are not described in greater detail here as they are understood by those knowledgeable of the prior art. The distal movement of the plunger or stopper 15 within themedicament cartridge 12 causes medication to be forced into theneedle 11 of thehub 20. Themedicament cartridge 12 is sealed byseptum 16, which is punctured by a septum penetratingneedle cannula 18 located within thehub 20. Thehub 20 is preferably screwed onto thelower housing 17, although other attachment means can be used, such as attaching to the cartridge. To protect a user, or anyone who handles thepen injection device 100, anouter cover 69, which attaches to thehub 20, covers the hub. Aninner shield 59 covers thepatient needle 11 within theouter cover 69. Theinner shield 59 can be secured to thehub 20 to cover the patient needle by any suitable means, such as an interference fit or a snap fit. Theouter cover 69 and theinner shield 59 are removed prior to use. Thecap 21 fits snugly againstouter sleeve 13 to allow a user to securely carry thedrug delivery pen 100. - The
medicament cartridge 12 is typically a glass tube sealed at one end with theseptum 16 and sealed at the other end with thestopper 15. Theseptum 16 is pierceable by aseptum penetrating cannula 18 in thehub 20, but does not move with respect to themedicament cartridge 12. Thestopper 15 is axially displaceable within themedicament cartridge 12 while maintaining a fluid tight seal. - Existing pen needle assemblies do not have means to adhere to a patient's skin during medication injection, thereby being prone to movement. Such movement can result in poor contact between the pen needle assembly and the patient's skin such that the needle is not accurately maintained in the intradermal layer during the injection. Therefore, a need exists for a pen needle assembly that provides good contact with the patient's skin to facilitate the intradermal medication injection.
- Existing pen needle assemblies also do not lift the outer layer of skin (the epidermal layer) during an intradermal injection. This can result in back pressure being generated during the injection, thereby resulting in a poor injection and leaking of the medication. Additionally, by not lifting the outer skin layer, the difficulty of injecting the medication into the intradermal layer is increased. Therefore, a need exists for a pen needle assembly that lifts the outer skin layer to facilitate intradermal medication injection into the intradermal layer and to substantially prevent generation of back pressure.
- Accordingly, a need exists for a pen needle assembly for a drug delivery pen that facilitates intradermal medication injection.
- In accordance with an aspect of the present invention, a pen needle assembly as defined in claim 1 is provided that provides improved contact with a patient's skin to facilitate intradermal medication injection.
- A pen needle assembly for a drug delivery pen for intradermal medication injection transmits a desired amount of a drug solution or suspension into a patient's intradermal layer both accurately and without loss of the drug solution or suspension.
- The pen needle assembly includes a user activated stamping mechanism that facilitates intradermal medication injection.
- The pen needle assembly includes an adhesive layer to provide good contact between the pen needle assembly and the patient's skin, in addition to maintaining the needle in the intradermal layer during an injection.
- The pen needle assembly lifts the outer layer of skin during the injection after the needle has been inserted, thereby reducing back pressure generated during the injection and substantially preventing leakage.
- The pen needle assembly may include a self-locking mechanism to substantially prevent the pen needle assembly from being re-used.
- Objects, advantages, and salient features of the invention will become apparent from the following detailed description, which, taken in conjunction with the annexed drawings, discloses exemplary embodiments of the invention.
- The above benefits and other advantages of the various embodiments of the present invention will be more apparent from the following detailed description of exemplary embodiments of the present invention and from the accompanying figures, in which:
-
FIG. 1 is a perspective view of an assembled drug delivery pen; -
FIG. 2 is an exploded perspective view of the components of the drug delivery pen ofFIG. 1 ; -
FIG. 3 is a perspective view in cross section of a pen needle assembly for a drug delivery pen for intradermal medication injection; and -
FIGS. 4 - 8 are elevational views in cross section illustrating operation of the pen needle assembly during an intradermal medication injection. - Throughout the drawings, like reference numbers will be understood to refer to like parts, components and structures.
- The following description and details of exemplary embodiments of the present invention, while generally disclosed with reference to a typical drug delivery pen, as shown in
FIGS. 1 and2 , may more broadly apply to a pen needle assembly for use in conjunction with, or incorporated onto, other injection devices, such as a syringe. - In the exemplary embodiments of the present invention shown in
FIGS. 3 - 8 , thepen needle assembly 111 includes anintradermal needle 121 fixed in amovable needle hub 131. Afirst end 143 of afirst spring 141 is connected to anouter shell 151, and asecond end 145 of the first spring is connected to aninner shell 171. Afirst end 163 of asecond spring 161 is connected to theinner shell 171, and thesecond end 165 of thesecond spring 161 is connected to themovable needle hub 131. Asafety cap 181, as shown inFIG. 5 , is disposed over theneedle 121. - The
outer shell 151 has abase 153 with anopening 155 therein. Awall 157 extends substantially perependicularly from thebase 153. Preferably, thebase 153 and theopening 155 are each substantially circular.Tabs 159 are diametrically opposed on aninner surface 158 of thewall 157 of theouter shell 151. Afree end 156 of thewall 157 is adapted to engage a patient's skin at an injection site. - The
inner shell 171 has afirst end 177 and asecond end 179 and is preferably substantially cylindrical.Threads 173 are disposed on aninner surface 172 thereof and are adapted to engage the lower housing 17 (FIG. 2 ). Aflange 174 extends outwardly from anouter surface 176 of the inner shell. Theflange 174 has anupper surface 178 and alower surface 170. Alocking prong 175 extends downwardly from alower surface 170 of theflange 174. - The
hub 131 has a base 133 with anopening 135 therein. Awall 137 extends substantially perependicularly from thebase 133. Preferably, thebase 133 and theopening 135 are each substantially circular.Flexible actuators 139 are formed in thewall 137 and are diametrically opposed. Aprojection 138 is formed at the free end of eachactuator 139. Theprojections 138 are adapted to engage thetabs 159 of theouter shell 151 prior to an injection. Aprotrusion 134 extends upwardly from aninner surface 132 of thebase 133. Apassageway 136 extends through the entirety of theprotrusion 134 to theopening 135 in thebase 133 of thehub 131. - A retaining
latch 201 has abase 203 and diametricallyopposed arms 205 extending upwardly therefrom. The base has anopening 207 adapted to receive thehub protrusion 134. Ahook 209 is formed at the free end of each of thearms 205. The hooks are adapted to engage the locking prongs 175 of theinner shell 171 prior to an injection. - An
upper surface 195 of theadhesive layer 191 is secured to alower surface 130 of thehub base 133. Preferably, the adhesive layer is substantially circular and corresponds to the shape of thehub base 133. Anopening 193 in theadhesive layer 191 is aligned with theopening 135 in thehub base 133. Alower surface 197 of theadhesive layer 191 is adapted to contact a patient's skin at the injection site during an injection. - A
first spring 141 is disposed between theouter shell 151 and theinner shell 171. Afirst end 143 of thefirst spring 141 is connected to thebase 153 of theouter shell 171 and asecond end 145 of thefirst spring 141 is connected to theupper surface 178 of theflange 174 of theinner shell 171. - A
second spring 161 is disposed between theinner shell 171 and thehub 131. Afirst end 163 of thesecond spring 161 is connected to thelower surface 170 of theflange 174 of theinner shell 171 and asecond end 165 of thesecond spring 161 is connected to theupper surface 132 of thehub base 133. - A
needle 121 is received by thepassageway 136 in thehub protrusion 134. Theneedle 121 has anon-patient end 123 that is adapted to pierce the cartridge septum 16 (FIG. 2 ) and apatient end 125 that passes through theopening 135 in thehub base 133 and is adapted to pierce a patient's skin at the injection site during an injection. - An assembled
pen needle assembly 111 is shown inFIG. 5 . Thethreads 173 of the inner shell receive a threaded portion of the lower housing 17 (FIG. 2 ), which is not shown inFIGS. 5 - 8 for clarity. Asafety cap 181 is disposed over theouter shell 151 and is secured thereto in any suitable manner, such as an interference fit. Thesafety cap 181 prevents an accidental needle stick. Prior to an injection, thefirst spring 141 between theouter shell 151 and theinner shell 171 is in a relaxed position. Thesecond spring 161 between theinner shell 171 and thehub 131 is in a compressed position. Thehook 209 of the retaininglatch 201 receives thelocking prong 175 of theinner shell 171, thereby preventing movement of the inner shell. Thehub projections 138 engage thetabs 159 of theouter shell 151, thereby preventing movement of thehub 131 and outer shell. - To perform an intradermal medication injection, the
safety cap 181 is removed. The drug delivery pen is pushed against the patient'sskin 211 such that thefree end 156 of theouter shell 151 contacts the patient's skin. Theouter shell 151 is moved upwardly (away from the patient's skin 211) along a longitudinal axis, as shown inFIG. 6 . This movement of theouter shell 151 causes thehub projections 138 to flex and move radially inwardly, thereby unlocking the locking mechanism between the retaininglatch hook 209 and thelocking prong 175. - As shown in
FIG. 7 , when thelatch hook 209 and thelocking prong 175 disengage, thesecond spring 161 is able to uncompress and extend. This movement of thesecond spring 161 urges themovable hub 131 and theneedle 121 downwardly, thereby inserting theneedle 121 into an intradermal layer of the patient'sskin 211 at theinjection site 213. This movement also causes thefirst spring 141 to become stretched. Theadhesive layer 191 on theneedle hub 131 adheres onto an outer layer of the patient'sskin 211. Thesecond spring 161 is then in either a relaxed or slightly compressed position. - As shown in
FIG. 8 , the pushing force on the drug delivery pen is released. Releasing such force on the inner shell, causes thefirst spring 141 to return to its original position, thereby lifting theinner shell 171, theneedle hub 131 and the patient'sskin 211 adhered to theadhesive layer 191 upwardly. The retraction of theneedle hub 131 lifts the adhered outer skin layer, thereby creating space in the intradermal layer to facilitate the intradermal medication injection. After the injection is complete, thepen needle assembly 111 is detached from the drug delivery pen 100 (FIGS. 1 and2 ) and is properly disposed of. - Preferably, the
hub projections 138 and theouter shell tabs 159 have sloped surfaces, as shown inFIG. 8 . Such sloped prevent upward movement of thehub 131, such that thepen needle assembly 111 cannot be re-used. Because thehub 131 cannot be moved past theprojections 159, thesecond spring 161 cannot be recompressed to drive another needle insertion. - The foregoing embodiments and advantages are merely exemplary and are not to be construed as limiting the scope of the present invention. The description of exemplary embodiments of the present invention is intended to be illustrative, and not to limit the scope of the present invention. Various modifications, alternatives and variations will be apparent to those of ordinary skill in the art, and are intended to fall within the scope of the invention as defined in the appended claims and their equivalents.
Claims (10)
- A pen needle assembly, comprising:an outer shell (151) having a first end adapted to engage a patient's skin at an injection site;a hub (131) movably disposed within said outer shell (151);a needle (121) rigidly fixed to said hub (131) and having a patient end (125) for piercing the skin at the injection site; andan adhesive layer (191) disposed on said hub (131) for contacting the skin at the injection site;an inner shell (171) within the outer shell (151),characterized bya first spring (141) having a first end connected to said outer shell (151) to retract said inner shell (171),a second spring (161) having a first end connected to said inner shell (171) and a second end connected to said hub (131),wherein said hub (131) moves downwardly during an injection to adhere said adhesive layer (191) on a patient's skin and moves upwardly to raise the patient's skin to facilitate the injection.
- A pen needle assembly according to claim 1, wherein
a tab (159) disposed on an inner surface (158) of said outer shell (151) engages a projection (138) disposed on said hub (131), thereby preventing upward movement of said hub (131) after an injection such that the pen needle assembly cannot be re-used. - A pen needle assembly, according to claim 1, wherein
said inner shell (171) is disposed within said outer (151) shell and engageable with a drug delivery device, said inner shell (171) being slidable within said outer shell (151);
said first spring (141) having a second end connected to said inner shell (171);
said second spring (161) is connected to said inner shell (171) and said hub (131) to bias said hub (131) away from said first end of said inner shell (171). - A pen needle assembly according to claims 1-3 comprising a medicament cartridge connected to said inner shell (171).
- The pen needle assembly according to claims 1 or 3, wherein a safety cap (181) is removably connected to said outer shell (151).
- The pen needle assembly according to claims 1 or 3, wherein a retaining latch (201) is disposed between said hub (131) and said inner shell (171) to prevent movement of said hub (131) relative to said inner shell (151) when said retaining latch (201) is engaged with said inner shell (171).
- The pen needle assembly according to claim 6, wherein said inner shell (171) has a locking prong (175) engaged by said retaining latch (201).
- The pen needle assembly according to claim 3, wherein a projection (138) on said hub (131) engages a tab (154) on said outer shell (151), thereby preventing upward movement of said hub (131) after an injection such that the pen needle assembly cannot be re-used.
- The pen needle assembly according to claim 6, wherein said first spring (141) is not compressed between said outer shell (151) and said inner shell (171) when said retaining latch (201) is engaged with said inner shell (171).
- The pen needle assembly according to claim 6, wherein said second spring (161) is compressed between said inner shell (171) and said hub (131) when said retaining latch (201) is engaged with said inner shell (171).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19323408P | 2008-11-07 | 2008-11-07 | |
PCT/US2009/006020 WO2010053574A1 (en) | 2008-11-07 | 2009-11-06 | Pen needle assembly for intradermal medication injection |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2349411A1 EP2349411A1 (en) | 2011-08-03 |
EP2349411A4 EP2349411A4 (en) | 2014-07-02 |
EP2349411B1 true EP2349411B1 (en) | 2017-03-01 |
Family
ID=42153148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09825133.3A Active EP2349411B1 (en) | 2008-11-07 | 2009-11-06 | Pen needle assembly for intradermal medication injection |
Country Status (6)
Country | Link |
---|---|
US (1) | US8945050B2 (en) |
EP (1) | EP2349411B1 (en) |
JP (1) | JP5524973B2 (en) |
CA (1) | CA2742814C (en) |
ES (1) | ES2626644T3 (en) |
WO (1) | WO2010053574A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2732778T3 (en) * | 2009-12-22 | 2019-11-25 | Becton Dickinson Co | Needle set with safety system with sliding locking tab |
CA2799241C (en) * | 2010-05-17 | 2017-06-13 | Becton, Dickinson And Company | Needle assembly with needle injection depth adjustment |
US8834418B2 (en) * | 2010-07-22 | 2014-09-16 | Covidien Lp | Molds for in situ forming materials |
US8961470B2 (en) | 2011-02-17 | 2015-02-24 | Steven Schraga | Pen needle with safety shield system |
EP2701784B1 (en) * | 2011-04-28 | 2015-07-22 | Sanofi-Aventis Deutschland GmbH | Dispense interface with lockout element |
GB2504128A (en) * | 2012-07-20 | 2014-01-22 | Oval Medical Technologies Ltd | Automatic injector with a skin contact element |
WO2014132240A1 (en) | 2013-02-28 | 2014-09-04 | Kimberly-Clark Worldwide, Inc. | Transdermal drug delivery device |
WO2015036947A1 (en) * | 2013-09-11 | 2015-03-19 | Debiotech S.A. | Needle insertion device |
US10118000B2 (en) | 2014-04-21 | 2018-11-06 | Stat Medical Devices, Inc. | Pen needle installation and removal safety cover and pen needle assembly utilizing the same |
US10155091B2 (en) | 2014-07-11 | 2018-12-18 | Stat Medical Devices, Inc. | Pen needle tip and method of making and using the same |
JP6073393B2 (en) * | 2015-02-23 | 2017-02-01 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | Needle assembly with needle injection depth adjustment |
US10646643B2 (en) * | 2016-01-21 | 2020-05-12 | West Pharma. Services IL, Ltd. | Needle insertion and retraction mechanism |
JP6885960B2 (en) | 2016-01-21 | 2021-06-16 | ウェスト ファーマ サービシーズ イスラエル リミテッド | Drug delivery device with visual indicators |
KR101623202B1 (en) | 2016-01-29 | 2016-05-23 | 박용택 | A tattooing device |
US10300203B2 (en) * | 2016-08-03 | 2019-05-28 | Min Wei | Priming mechanism for automatic injection device |
CA3126999A1 (en) | 2019-02-22 | 2020-08-27 | Deka Products Limited Partnership | Infusion set and inserter assembly systems and methods |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6743211B1 (en) * | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
US7141034B2 (en) * | 2000-06-08 | 2006-11-28 | Altea Therapeutics Corporation | Transdermal drug delivery device, method of making same and method of using same |
US6986760B2 (en) | 2000-08-02 | 2006-01-17 | Becton, Dickinson And Company | Pen needle and safety shield system |
WO2004032989A2 (en) | 2002-07-08 | 2004-04-22 | Medical Instill Technologies, Inc. | Intradermal delivery device adhesively attachable to the skin, and method of intradermal delivery |
JP2005538773A (en) * | 2002-09-12 | 2005-12-22 | チルドレンズ ホスピタル メディカル センター | Method and apparatus for injecting drugs without pain |
US6896666B2 (en) * | 2002-11-08 | 2005-05-24 | Kochamba Family Trust | Cutaneous injection delivery under suction |
EP1696983A2 (en) * | 2003-12-18 | 2006-09-06 | Novo Nordisk A/S | Nozzle device with skin stretching means |
EP1814616A1 (en) * | 2004-11-04 | 2007-08-08 | Sid Technologies Llc | Automatic injector |
US20070156096A1 (en) | 2005-11-10 | 2007-07-05 | Terumo Kabushiki Kaisha | Puncture device |
US7842008B2 (en) | 2005-11-21 | 2010-11-30 | Becton, Dickinson And Company | Intradermal delivery device |
US7871397B2 (en) | 2006-12-26 | 2011-01-18 | Stat Medical Devices, Inc. | Pen needle tip |
WO2009039013A1 (en) * | 2007-09-17 | 2009-03-26 | Icu Medical, Inc. | Insertion devices for infusion devices |
-
2009
- 2009-11-06 WO PCT/US2009/006020 patent/WO2010053574A1/en active Application Filing
- 2009-11-06 ES ES09825133.3T patent/ES2626644T3/en active Active
- 2009-11-06 US US13/127,440 patent/US8945050B2/en active Active - Reinstated
- 2009-11-06 CA CA2742814A patent/CA2742814C/en active Active
- 2009-11-06 EP EP09825133.3A patent/EP2349411B1/en active Active
- 2009-11-06 JP JP2011535565A patent/JP5524973B2/en active Active
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
JP5524973B2 (en) | 2014-06-18 |
CA2742814C (en) | 2017-03-07 |
US20110288526A1 (en) | 2011-11-24 |
JP2012508059A (en) | 2012-04-05 |
WO2010053574A1 (en) | 2010-05-14 |
US8945050B2 (en) | 2015-02-03 |
EP2349411A4 (en) | 2014-07-02 |
ES2626644T3 (en) | 2017-07-25 |
CA2742814A1 (en) | 2010-05-14 |
EP2349411A1 (en) | 2011-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2349411B1 (en) | Pen needle assembly for intradermal medication injection | |
US11135371B2 (en) | Apparatuses and method for injecting medicaments | |
EP2221078B1 (en) | Pen needle assembly for preventing under-torquing and over-torquing of pen needle | |
EP2853277B1 (en) | Prefilled safety pen needle | |
EP2298397B1 (en) | Outer cover of a pen needle for a drug delivery pen | |
US8328766B2 (en) | Medical needle safety devices | |
EP3308810B1 (en) | Needle changing apparatus | |
JP5629775B2 (en) | Self-injector | |
US20140288528A1 (en) | Single-use needle assembly and method | |
EP2506897B1 (en) | Pen needle removal device for a drug delivery device | |
EP2393537B1 (en) | Disposable pen needle with re-use prevention features | |
EP2393531B1 (en) | Pen needle to facilitate manipulation by users having physical or visual impairment | |
TW201509472A (en) | Syringes | |
US20060111676A1 (en) | Passively guarded, pre-filled injection syringe | |
WO2018215605A1 (en) | System for safe handling of medical needle unit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110527 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20140603 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61M 5/50 20060101ALN20140527BHEP Ipc: A61M 5/42 20060101ALI20140527BHEP Ipc: A61M 5/46 20060101ALI20140527BHEP Ipc: A61M 5/20 20060101AFI20140527BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160729 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BECTON, DICKINSON AND COMPANY |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
INTC | Intention to grant announced (deleted) | ||
GRAR | Information related to intention to grant a patent recorded |
Free format text: ORIGINAL CODE: EPIDOSNIGR71 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
INTG | Intention to grant announced |
Effective date: 20170120 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 870550 Country of ref document: AT Kind code of ref document: T Effective date: 20170315 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602009044553 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20170301 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 870550 Country of ref document: AT Kind code of ref document: T Effective date: 20170301 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2626644 Country of ref document: ES Kind code of ref document: T3 Effective date: 20170725 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170602 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170601 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170601 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170703 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170701 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602009044553 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
26N | No opposition filed |
Effective date: 20171204 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171130 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171106 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20171130 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171106 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20091106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20221021 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20221020 Year of fee payment: 14 Ref country code: GB Payment date: 20221021 Year of fee payment: 14 Ref country code: ES Payment date: 20221201 Year of fee payment: 14 Ref country code: DE Payment date: 20221020 Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602009044553 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20231106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240601 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231130 |